The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Hims & Hers Health Inc. shares valued at $60,594 were sold by Becklund Irene on Sep 20. At $5.68 per share, Becklund Irene sold 10,668 shares. The insider’s holdings dropped to 6,978 shares worth approximately $38169.659999999996 following the completion of this transaction.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
Also, O’Keefe Lynne Chou sold 10,046 shares, netting a total of over 57,061 in proceeds. Following the sale of shares at $5.68 each, the insider now holds 0 shares.
Before that, Becklund Irene had sold 11,002 shares from its account. In a trade valued at $73,053, the PAO traded Hims & Hers Health Inc. shares for $6.64 each. Upon closing the transaction, the insider’s holdings decreased to 11,002 shares, worth approximately $14851.05.
As published in their initiating research note from Truist on September 07, 2022, Hims & Hers Health Inc. [HIMS] has been a Hold and the price target has been revised to $7. This represents a 21.86% premium over Thursday’s closing price. Analysts at SVB Leerink started covering the stock with ‘”an Underperform”‘ outlook in a report released in mid July. As of April 14, 2022, Guggenheim has initiated its “Buy” rating for HIMS.
Analyzing HIMS’s Price Performance
On Thursday, Hims & Hers Health Inc. [NYSE: HIMS] plunged -3.70% to $5.47. The stock’s lowest price that day was $5.335, but it reached a high of $5.655 in the same session. During the last five days, there has been a drop of approximately -9.29%. Over the course of the year, Hims & Hers Health Inc. shares have dropped approximately -16.49%. Shares of the company reached a 52-week high of $7.28 on 08/15/22 and a 52-week low of $2.72 on 05/12/22. A 50-day SMA is recorded $6.20, while a 200-day SMA reached $5.19. Nevertheless, trading volume fell to 1.18 million shares from 0.9 million shares the previous day.
Support And Resistance Levels for Hims & Hers Health Inc. (HIMS)
According to the 24-hour chart, there is a support level at 5.32, which, if violated, would cause prices to drop to 5.17. In the upper region, resistance lies at 5.64. The next price resistance is at 5.81. RSI (Relative Strength Index) is 35.75 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.47, which suggests the price will decrease in the coming days. Percent R is at 90.46%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Hims & Hers Health Inc. subject to short interest?
Stocks of Hims & Hers Health Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 3.03 million shares to 12.31 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 9.28 million shares. A jump of 24.61% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.44 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.44.
Which companies own the most shares of Hims & Hers Health Inc. (HIMS)?
According to The Vanguard Group, Inc. filings, the company currently owns 10,938,001 shares, which is about 5.50% of the total HIMS shares outstanding. The investor’s shares have appreciated by 1,937,761 from its previous 13-F filing of 9000240.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $48,067,347. A total of 1,085,736 shares of Hims & Hers Health Inc. were bought by Marshall Wace LLP during the quarter, and 1,126,884 were bought by Geode Capital Management LLC. In its current portfolio, Renaissance Technologies LLC holds 1,959,100 shares valued at $12.46 million.
In terms of Hims & Hers Health Inc. share price expectations, FactSet research, analysts set an average price target of $7.83 in the next 12 months, up nearly 40.85% from the previous closing price of $5.68. Analysts anticipate Hims & Hers Health Inc. stock to reach $12.00 by 2022, with the lowest price target being $5.00. In spite of this, 9 analysts ranked Hims & Hers Health Inc. stock as an Overweight at the end of 2022. On March 10, 2022, Deutsche Bank assigned a price target of “a Hold” to the stock and initiated coverage with a $7.